Full-Time
Senior Financial Analyst
Financial Modeling & Analytics
Progyny
501-1,000 employees
Fertility benefits management for employers
Compensation Overview
$90k - $110k/yr
No H1B Sponsorship
New York, NY, USA
Hybrid
Three days in the office per week are required for employees reporting into the New York office.
Bachelor's, MBA
 Finance & Banking (1) |
|---|
Get referred to Progyny
See people who can refer or advise you
- At least 3 years of progressive experience in financial planning and analysis, corporate finance, investment banking, consulting, or a similar analytical role.
- A bachelor's degree in Accounting or Finance.
- Advanced Excel and Power BI skills, strong data-query experience, and the ability to manipulate and interpret large data sets.
- Knowledge of generally accepted accounting principles and financial statement presentation.
- The ability to plan and prioritize work, align commitments with organizational goals, break down objectives into initiatives and actions, establish milestones, and adjust plans when needed.
- The ability to communicate complex information clearly and concisely across one-on-one, small-group, and large-group settings.
- Situational adaptability and resourcefulness.
- A continuous-improvement mindset.
- Authorization to work in the United States without sponsorship, now or in the future.
- Develop and maintain client-level financial models to assess performance guarantees, incorporating contractual terms, key assumptions, and potential financial outcomes.
- Track actual results against performance guarantees, investigate variances, and identify emerging financial risks and opportunities.
- Translate complex modeling and performance results into clear, actionable insights for finance, account management, and senior leadership stakeholders.
- Perform scenario and sensitivity analyses to inform guarantee structure, pricing, and contract negotiations.
- Support the Accounting team’s monthly close and month-end variance analysis.
- Own, maintain, and improve internal models, dashboards, and analyses.
- Identify and analyze operational problems and recommend effective solutions.
- Work closely with cross-functional teams on complex ad hoc projects and reporting.
- Experience combining financial accounting and reporting.
- Experience at a publicly traded company.
- Experience using or implementing financial planning software.
- An MBA.
Progyny is a fertility benefits manager that partners with employers to offer comprehensive fertility and family-building services to employees. It provides a wide range of services including IUI, IVF, fertility preservation, adoption assistance, and surrogacy support, all integrated into employers’ existing benefits packages. The company makes money by signing contracts with employers, typically using a fixed-fee or per-employee-per-month pricing model, and it works to deliver better clinical outcomes to reduce overall treatment costs. Unlike broader health insurers, Progyny focuses specifically on fertility care and family-building, emphasizing measurable clinical results and seamless workflow within the benefits ecosystem. Its goal is to expand access to inclusive fertility benefits while improving outcomes and controlling costs for employers and employees.
Company Size
501-1,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
2008
Get referred to Progyny
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $350.5 million, up 11% excluding the transition client.
- Management reaffirmed 2026 revenue of $1.36 billion to $1.385 billion after strong sales momentum.
- Progyny repurchased 1.2 million shares for $31.5 million, signaling confidence and supporting EPS.
What critics are saying
- Q3 2026 guidance assumes softer summer engagement, exposing fragile utilization seasonality.
- A former large client already cut 2025 revenue by $48.5 million, showing renewal risk.
- Carrot, Maven, Kindbody, and health-plan bundles pressure Progyny’s pricing; one lost enterprise account hurts fast.
What makes Progyny unique
- Progyny’s Smart Cycle model bundles fertility care, medications, and concierge navigation for employers.
- Its contracted clinic network concentrates volume, supporting 25.5% gross margin in Q2 2026.
- Zero debt and $236.9 million cash give Progyny unusual balance-sheet flexibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Performance Bonus
Family Planning Benefits
Fertility Treatment Support
Wellness Program
Mental Health Support
Company Social Events
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Two healthcare companies with strong cash positions are attracting investor attention, whilst a fertility benefits provider faces challenges. Progyny holds $214.4 million in net cash, representing 14.2% of its market capitalisation. However, the company has struggled with underwhelming unit sales over the past two years and demonstrates below-average returns on capital. Trading at $27.95 per share, Progyny commands a 13.9x forward price-to-earnings ratio. Molina Healthcare maintains a net cash position of $1.22 billion, or 11.9% of market cap. The managed healthcare provider has achieved 13.7% annual revenue growth over five years, outpacing sector averages. Operating across 21 states, Molina serves low-income individuals through Medicaid, Medicare, and Marketplace programmes. Axos Financial, a digital banking and financial services company, holds $39.48 million in net cash, though this represents just 0.7% of its market capitalisation.
Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. August 07, 2026 10:51:30 am NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. Market Wire News envision a world where everyone can realize their dreams of family and ideal health. Its outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Its benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected]
Progyny reported record quarterly revenue and adjusted EBITDA for Q2 2026. Second quarter revenue rose 5.3% year-over-year, or 11% excluding contributions from a large former client under a transition agreement in Q2 2025. The fertility benefits provider's gross margin expanded 180 basis points year-over-year, driven by efficiencies in care management and service delivery. Operating cash flow reached more than $50 million for the fourth time in five quarters. Progyny repurchased nearly 1.2 million shares for $31.5 million during the quarter under its $200 million programme. Since November, the company has bought back 10.8 million shares, reducing shares outstanding by approximately 12.5%. The company projects full-year 2026 revenue between $1.36 billion and $1.385 billion, representing growth of 5.5% to 7.5%.
Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Fertility benefits company Progyny reported second-quarter results for 2026, with revenue of $350.5 million, beating analyst expectations by 0.6% and representing 5.3% year-on-year growth. The company's non-GAAP earnings per share of $0.55 also exceeded estimates by 6.2%. Despite the positive quarterly results, Progyny's stock dropped 10.2% following disappointing forward guidance. The company's revenue forecast for the next quarter of $340 million came in 3% below analyst estimates. Progyny also lowered its full-year revenue guidance to $1.37 billion from $1.39 billion, a 0.9% decrease. Chief Executive Officer Pete Anevski attributed the strong quarterly results to member engagement trending toward the higher end of expectations.